NCT00859469 · OUTCOME

Overall Survival

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma · Source last updated 2019-10-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 50 months

Analysis population: ITT

Groups in this outcome

Oxaliplatin and Gemcitabine

The study drugs will be administered in the following manner: Gemcitabine, at 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin, at 100 mg/m² IV infusion over 2 hours.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Oxaliplatin and Gemcitabine	29

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Oxaliplatin and Gemcitabine	8	Not reported	4	14	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
4
upper Limit
14
value
8

denoms

counts
group Id
OG000
value
29
units
Participants

dispersion Type

95% Confidence Interval

groups

description
The study drugs will be administered in the following manner: Gemcitabine, at 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin, at 100 mg/m² IV infusion over 2 hours.
id
OG000
title
Oxaliplatin and Gemcitabine

param Type

MEDIAN

population Description

ITT

reporting Status

POSTED

time Frame

50 months

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice